Literature DB >> 1532603

The Miller Fisher syndrome. Review of the literature.

P Berlit1, J Rakicky.   

Abstract

The triad of ataxia, areflexia and ophthalmoplegia was first described as a variant of the Guillain-Barre syndrome in 1932 by Collier. In 1956, Miller Fisher reported three patients with ataxia, areflexia, and ophthalmoplegia as a separate entity. Since then, 223 cases of Miller Fisher syndrome have been published. The male/female ratio is 2:1 with a mean age of 43.6 years at the onset of the disease. A viral infection preceded the neurological symptoms in 71.8% of cases with an average symptom-free interval of 10 days. First symptoms were diplopia (38.6%) or ataxia (20.6%). An areflexia was present in 81.6% of cases. Cranial nerves other than the oculomotor nerves were involved in 127 cases (56.9%): cranial nerves 7 (45.7%), 9 and 10 (39.9%), and 12 (13%) were involved. In 53 cases a tetraparesis occurred. An elevated protein value was present in 134 patients (64.4%); cerebrospinal fluid findings were normal in 56 patients. Eighteen patients showed a mild pleocytosis. Besides the cerebellar type of ataxia, initial disturbances of consciousness (n = 8), supranuclear oculomotor signs (n = 22), and pathology findings in electroencephalography (n = 38), computed tomography (n = 8), and magnetic resonance imaging (n = 2) were reported as evidence for a central nervous system involvement in the Miller Fisher syndrome. The prognosis of Miller Fisher syndrome was good--recovery occurred after a mean time period of 10.1 weeks. Residual symptoms were present in 74 cases (33.2%), and a recidivism of the Miller Fisher syndrome was reported in seven patients. Eight patients died. Of six patients with autopsy findings, four exhibited central nervous system lesions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1532603

Source DB:  PubMed          Journal:  J Clin Neuroophthalmol        ISSN: 0272-846X


  20 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

2.  Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.

Authors:  B Schwerer; A Neisser; H Bernheimer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Fisher syndrome.

Authors:  Masahiro Mori; Satoshi Kuwabara
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

4.  Miller Fisher Syndrome: A Case Report Highlighting Heterogeneity of Clinical Features and Focused Differential Diagnosis.

Authors:  Ilya V Yepishin; Randall Z Allison; David A Kaminskas; Natalia M Zagorski; Kore K Liow
Journal:  Hawaii J Med Public Health       Date:  2016-07

Review 5.  [Miller Fisher syndrome: case report and review with discussion of differential diagnosis and nosology].

Authors:  U Becker; G Gahn; H Reichmann; B Herting
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

6.  Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome.

Authors:  A Neisser; H Bernheimer; T Berger; A P Moran; B Schwerer
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

7.  Miller Fisher syndrome in infancy.

Authors:  J Benito-León; J Bravo; F Mateos; R Simón
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

Review 8.  Neuro-ophthalmology and the Anti-GQ1b antibody syndromes.

Authors:  Robert F Saul
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

9.  An unusual case of Parinaud's syndrome.

Authors:  Maria Mallia; Charmaine Chircop; Josanne Aquilina
Journal:  BMJ Case Rep       Date:  2012-11-21

10.  Cerebrospinal fluid total protein in Guillain-Barré syndrome variants: correlations with clinical category, severity, and electrophysiology.

Authors:  Pierre R Bourque; J Brooks; J Warman-Chardon; A Breiner
Journal:  J Neurol       Date:  2019-11-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.